Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis

Objective To systematically evaluate the efficacy of mycophenolate mofetil (MMF) compared with the standard treatment for autoimmune hepatitis. Methods Medline (PubMed), Embase, and Cochrane Library databases were searched between 1966 and June 2018 for studies on prednisone and/or azathioprine/mycophenolate mofetil in autoimmune hepatitis. The keywords and descriptor terms used were ‘hepatitis’, ‘autoimmunity’, ‘prednisone’, ‘prednisolone’, ‘azathioprine’, and ‘mycophenolate mofetil’. The Z test and Cochrane Q test were used in the statistical analysis. Results Seven hundred and eighty-eight related articles were found; 779 studies were excluded after further review. Ultimately, seven studies (583 participants) were included. The remission rate of aminotransferase and immunoglobulin (Ig)-G levels with standard treatment was 33.33–86.67%, and the nonresponse rate was 15.15–66.67%. Although the remission rate of the aminotransferase level with prednisone and MMF was 55.17–88.89% and that of the IgG level was 61.16–88.89%, the nonresponse rate was 6.42–33.33%. Remission rates of the aminotransferase level (P
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research